Nieuws en video's - NATERA INC.

NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA PR Newswire NEW ORLEANS, Oct. 20, 2023 NEW ORLEANS , Oct. 20, 2023 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA). On March 14, 2022 , a jury found that the...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX). The MolDX technology assessment program has determined that Prospera Lung will be covered under the existing Medicare Local Coverage Determination for...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 million in the second quarter of 2022, an increase of 31.9%. Product revenues grew 32.7% over the same period. Processed approximately 617,200 tests in the second quarter of 2023, compared to approximately 499,900...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA. A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at investor.natera.com . A replay of the event will be available shortly following the conference. About Natera Natera™...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility of the Signatera molecular residual disease (MRD) test in patients with stage II-IV resectable colorectal cancer (CRC). CIRCULATE-Japan also...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2023, after the market close on Aug. 3, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Second Quarter 2023 Financial Results Date: Thursday, Aug. 3, 2023 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1 (888) 770-7321 (Domestic) 1...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA. A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at investor.natera.com . A replay of the event will be available shortly following the conference. About Natera...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection in kidney transplant patients, as well as additional presentations that showcase the utility of...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 – 6, 2023. Signatera and Natera’s circulating tumor DNA (ctDNA) technology will be featured across a wide variety of cancers, including colorectal (CRC), lung, bladder, esophageal, pancreatic,...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement suit it filed against ArcherDX/Invitae Corp. The jury found that all accused ArcherDX/Invitae products infringe three of Natera’s patents. The jury determined that all three patents are valid and awarded both past lost profits and a past royalty of 10%, totaling...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the same period. Processed approximately 626,200 tests in the first quarter of 2023, compared to approximately 489,300 tests...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery). Up to 50% of newly diagnosed breast cancer patients receive NAC. 2 While patients...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s First Quarter 2023 Financial Results Date: Tuesday, May 9, 2023 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1 (888) 770-7321, Domestic 1 (929)...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American Association for Cancer Research (AACR) taking place April 14 – 19, 2023. Natera and its collaborators will present findings from five studies on Signatera in esophago-gastric adenocarcinoma, muscle-invasive bladder cancer (MIBC), colorectal cancer (CRC) and hepatocellular carcinoma (HCC)....

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in patients with stages III-IV melanoma. The full study can be found here . This study analyzed 555 prospectively collected plasma samples from 69...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring. Effective March 1, 2023, Blue Shield of California now provides commercial coverage of Signatera for plan members diagnosed with any solid tumors. Specifically, the policy describes tumor-informed...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights Generated total revenues of $217.3 million in the fourth quarter of 2022 compared to $173.0 million in the fourth quarter of 2021, an increase of 25.6%. Product revenues grew 28.2% over the same period. Generated total revenues of...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences: Raymond James 44th Annual Institutional Investors Conference on Tuesday, March 7 at 2:50 p.m. ET in Orlando, FL Cowen 43rd Annual Health Care Conference on Wednesday, March 8 at 11:10 a.m. ET in Boston, MA A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company’s board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/ (Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS),...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Fourth Quarter and Year-End 2022 Financial Results Date: Tuesday, Feb. 28, 2023 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1...